CagriSema vs Wegovy: Should You Wait, or Start Wegovy Now?
The honest 2026 answer — including the trial CagriSema lost, and the new Wegovy forms most comparisons miss.
By The RX Index Research Team · Last verified: . The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission from some provider links — that never changes what we verify or whether we send you to a non-affiliate route when that’s the better answer. CagriSema cannot be bought or prescribed by a U.S. pharmacy outside clinical research. This page is for comparison and pricing research only — not medical advice.
CagriSema vs Wegovy comes down to one thing most articles skip: you can’t actually get CagriSema yet. In the REDEFINE 1 trial, CagriSema produced more weight loss than the Wegovy dose tested in the same study — about 22.7% versus 16.1% if people stayed on treatment as directed (or 20.4% versus 14.9% counting everyone who started). That sounds like a clear win. But CagriSema is not FDA-approved. Novo Nordisk filed its application in December 2025 and the FDA is reviewing it in 2026 — and in the only direct trial against Zepbound, CagriSema lost. Meanwhile, Wegovy added a daily pill and a higher-dose shot you can get now.
CagriSema vs Wegovy at a glance
Here’s the whole decision in one screen. The rest of this page explains every row.
| Bottom line | CagriSema | Wegovy (the full family now) |
|---|---|---|
| Can you get it today? | No | Yes |
| FDA-approved? | No — application filed Dec 2025 | Yes |
| Best weight loss if taken as directed | ~22.7% (REDEFINE 1) | ~16.1% standard shot (REDEFINE 1); ~20.7% Wegovy HD (STEP UP); ~16.6% pill (OASIS 4) |
| Weight loss counting everyone who started | ~20.4% (REDEFINE 1) | ~14.9% standard shot (REDEFINE 1); ~13.6% pill (OASIS 4) |
| Head-to-head trial result | Lost to Zepbound, 20.2% vs 23.6% (REDEFINE 4) | Zepbound beat the standard shot, 20.2% vs 13.7% (SURMOUNT-5) |
| Forms | Weekly shot (under review) | Weekly shot, daily pill, Wegovy HD shot |
| Current price | Not announced | ~$149–$399/mo depending on form; $0–$25/mo with some insurance |
| Best next step | Watch the FDA decision | Check coverage, then talk to a clinician |
Last verified: . Numbers above come from each drug’s own clinical trials — these are separate studies, not head-to-head, except where noted (REDEFINE 4 and SURMOUNT-5).
Need an FDA-approved option you can actually start?
Ro offers a free GLP-1 Insurance Coverage Checker — you enter your insurance details, Ro reaches out to your plan, and sends back a personalized report showing whether your policy covers Wegovy, whether prior authorization is needed, and any copay or cost estimates. Free even if you’re not a member.
Worried about “CagriSema vials” you’ve seen online? Jump to the FDA warning ↓
Why people search this: most readers are trying to answer four practical questions — how effective CagriSema is, whether it quiets the constant “food noise,” whether the vials sold online are legitimate, and whether nausea could be worse than on Wegovy. We answer all four below.
What’s the actual difference between CagriSema and Wegovy?
CagriSema is two drugs in one shot; Wegovy is one drug in several forms. CagriSema combines semaglutide (the same medicine in Wegovy and Ozempic) with cagrilintide, a second medicine that works on a different appetite pathway. Wegovy is semaglutide on its own — but it now comes as a weekly shot, a once-daily pill, and a new higher-dose shot. So CagriSema adds a second ingredient, while Wegovy adds more ways to take it.
CagriSema = semaglutide + an “amylin” drug
The “Sema” in CagriSema is semaglutide, a GLP-1 receptor agonist — a medicine that copies a gut hormone to lower hunger and slow digestion. The “Cagri” is cagrilintide, an amylin analogue — a medicine that copies amylin, another hormone your body releases after eating that helps you feel full. Novo Nordisk describes CagriSema as a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in one weekly injection.
The idea is simple: hit two “I’m full” pathways instead of one. In trials, that combination did produce more weight loss than semaglutide alone. What it does not do is make CagriSema a “stronger Wegovy.” It’s a different, more complex medicine — and a brand-new one with a shorter safety track record.
Wegovy is no longer just one shot
This is the part older comparisons miss. The Wegovy family in 2026 includes:
- Wegovy injection (2.4 mg): the original weekly shot, FDA-approved in 2021 for weight management, and also approved to lower heart risk in certain adults.
- Wegovy pill (oral semaglutide): approved December 22, 2025 and broadly available since January 2026. It’s the first and only oral GLP-1 FDA-approved for weight loss in adults, taken once daily. See our Wegovy pill cost guide.
- Wegovy HD (7.2 mg): a higher-dose weekly shot, FDA-approved March 19, 2026, for adults who’ve tolerated the 2.4 mg dose for at least four weeks and need more weight reduction. See our Wegovy HD guide.
If you’ve only ever compared CagriSema to the old 2.4 mg Wegovy shot, you’re comparing it to a 2024 version of the choice. The real-world question is CagriSema versus the current Wegovy lineup.
Is CagriSema better than Wegovy for weight loss?
On paper, in one trial, CagriSema lost more weight than the Wegovy dose tested beside it — but that edge shrinks once you look at Wegovy HD. In REDEFINE 1, CagriSema averaged 22.7% weight loss (or 20.4% counting everyone), versus 16.1% (or 14.9%) for semaglutide 2.4 mg in the same study. That’s a real difference. But Wegovy HD, which you can get now, reached about 20.7% — so the “much stronger” story doesn’t hold up the way the headlines suggest.
The honest, same-trial comparison (this is the number that counts)
The cleanest comparison comes from inside one study — REDEFINE 1 — where CagriSema and the exact Wegovy dose (semaglutide 2.4 mg) were tested in the same 3,417 people, over the same 68 weeks, under the same rules. Same patients, same protocol, no apples-to-oranges.
| REDEFINE 1 (same trial, no diabetes, 68 weeks) | CagriSema | Wegovy’s dose (sema 2.4 mg) | Placebo |
|---|---|---|---|
| Weight loss if taken as directed | 22.7% | 16.1% | 2.3% |
| Weight loss counting everyone who started | 20.4% | 14.9% | 3.0% |
| Reached 25%+ weight loss | 40.4% | 16.2% | 0.9% |
| Reached 5%+ weight loss | 91.9% | — | 31.5% |
Source: Novo Nordisk’s REDEFINE 1 results, published in the New England Journal of Medicine and presented at the American Diabetes Association.
So yes — in this trial, CagriSema beat the Wegovy dose. But the gap is about 6 percentage points, not “twice as powerful.” And the bigger point: this does not make CagriSema available.
Why you keep seeing two different numbers (22.7% vs 20.4%)
If you’ve seen CagriSema quoted as both “22.7%” and “20.4%,” neither is wrong. They’re two ways of measuring the same trial:
- The 22.7% number is the “if everyone stayed on treatment as planned” result (the trial-product estimand). It’s the best-case, sticking-with-it number.
- The 20.4% number counts everyone who started, including people who stopped early or added other therapies (the treatment-policy estimand). It’s closer to what day-to-day use looks like.
Real results usually land nearer the lower number. We show both because the best-case figure can make a brand-new drug look more certain than everyday use will be.
Want to know what you can actually start now?
Ro’s free GLP-1 Insurance Coverage Checker tells you whether your plan covers Wegovy and whether you’ll need prior authorization — before you pay anything.
See if your insurance covers Wegovy → (sponsored affiliate link, opens in a new tab)CagriSema vs Wegovy HD: does the newer Wegovy dose close the gap?
Mostly, yes. CagriSema has the higher number in its own trial — about 22.7% if taken as directed — but Wegovy HD, the higher-dose shot the FDA approved in March 2026, reached about 20.7% in its STEP UP trial, with roughly one in three people losing 25% or more. There’s no direct CagriSema-vs-Wegovy HD trial, so this isn’t a “winner” declaration — it’s a pipeline drug versus an approved option you can get today.
For years, “CagriSema vs Wegovy” meant CagriSema versus the old 2.4 mg shot at about 15%. That made CagriSema look like a big leap. But in March 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg), and in its STEP UP trial of roughly 1,400 adults it produced a mean weight loss of about 20.7%. It’s meant for people who’ve already taken the 2.4 mg dose for at least four weeks and need more reduction.
Line the two up carefully — these are different trials with different patients, not a head-to-head — and the gap nearly closes:
Numbers in context (not a head-to-head):
- CagriSema (REDEFINE 1): ~22.7% if taken as directed • ~20.4% counting everyone
- Wegovy HD (STEP UP): ~20.7% if taken as directed — FDA-approved, available now
We’re not declaring a winner across two separate studies. But the takeaway is clear: an FDA-approved semaglutide you can get today already reaches CagriSema’s range. The case for waiting a year or more for a few extra points on paper gets a lot weaker.
Our one honest admission: If the single highest number on a chart is the only thing you care about, CagriSema’s 22.7% does edge out everything available right now. We won’t pretend otherwise. But CagriSema isn’t FDA-approved, you can’t buy it, and — as you’ll see next — it lost the only direct trial it ran against Zepbound, another drug you can get today.
But CagriSema lost to Zepbound — what that means for you
In the only direct CagriSema-vs-Zepbound trial, CagriSema lost. In REDEFINE 4, CagriSema produced 20.2% weight loss versus 23.6% for Zepbound (tirzepatide) over 84 weeks, and it failed to prove it was even as good as Zepbound. So the “most powerful GLP-1” framing is shaky — a drug already on pharmacy shelves beat it.
In February 2026, Novo Nordisk reported results from REDEFINE 4, a head-to-head trial of 809 adults that tested CagriSema directly against Zepbound. The goal was to show CagriSema was “non-inferior” — at least as good. It didn’t get there:
| REDEFINE 4 head-to-head (84 weeks, 809 adults) | CagriSema | Zepbound (tirzepatide) |
|---|---|---|
| If taken as directed (efficacy estimand) | 23.0% | 25.5% |
| Counting everyone (treatment-regimen estimand) | 20.2% | 23.6% |
| Non-inferiority primary endpoint met? | No — failed | — |
Why this matters more than the Wegovy comparison: Zepbound is FDA-approved and available right now. So the most direct evidence we have says a medicine you can already get outperformed CagriSema. If you’re holding off on treatment because you think CagriSema will be the strongest thing on the market, the only direct test so far points the other way.
None of this means CagriSema is a bad drug — Novo Nordisk is testing higher doses, with more data expected in 2027, and it may still earn approval. It just means the case for waiting is much weaker than it looks. For a deeper look, see our CagriSema vs Zepbound breakdown.
Can you get CagriSema right now?
No. CagriSema is not FDA-approved and cannot be prescribed or dispensed by a U.S. pharmacy outside clinical research as of June 2026.
Novo Nordisk filed its application in December 2025, but an application is not an approval — the drug can’t be dispensed like Wegovy until the FDA acts, the company launches it, and pharmacies stock it. Anything sold online today as “CagriSema” is not the real, approved product.
The FDA status, in plain terms
CagriSema is investigational — still under review. Novo Nordisk submitted its application on December 18, 2025, and the FDA is reviewing it in 2026, with a decision widely expected late in the year. If approved, a launch could follow in late 2026 or 2027. Timelines often slip, so treat any “coming this spring” promise with caution. For the full regulatory timeline, see our CagriSema FDA approval status guide.
Can CagriSema be compounded? No — and this is important
You may have seen “compounded CagriSema,” “cagrilintide vials,” or “research peptides” for sale. Here’s the straight answer: the FDA states that cagrilintide cannot be used in compounding under federal law, that it is not a component of any FDA-approved drug, and that it has not been found safe and effective for any condition.
Translation: there is no legal, FDA-sanctioned way to get cagrilintide — or “CagriSema” — compounded today. The FDA has sent warning letters to companies selling unapproved GLP-1 ingredients, often labeled “for research use only” or “not for human consumption” while clearly being marketed to people for weight loss.
🚩 Red flags that a “CagriSema” offer is not legitimate:
“CagriSema vial,” “research peptide,” “not for human consumption,” “no prescription needed,” “cagrilintide stack,” or “compounded CagriSema.”
Safer move: talk to a licensed clinician about FDA-approved options that exist right now. There are several, and their labels are based on FDA-reviewed evidence.
We’d rather lose your click than send you toward an unapproved vial. That’s the whole point of this page.
If you want a legal, FDA-approved path you can start now:
Ro’s free GLP-1 Insurance Coverage Checker is open to everyone — not just members — and reports whether your plan covers Wegovy, whether prior authorization is required, and any copay or cost estimates.
Check your coverage free → (sponsored affiliate link, opens in a new tab)Should you wait for CagriSema or start Wegovy now?
For most people: don’t wait. If you want treatment in the next 30 to 90 days and you can access an FDA-approved option, waiting means delaying real progress for a drug that isn’t approved, isn’t priced, and lost its only direct trial against Zepbound. Waiting makes sense only in a narrow case: you’re stable, not in a rush, and you specifically want to reassess CagriSema after the FDA decides.
Find your situation in this table
| Your situation | Smarter move right now | Why |
|---|---|---|
| Not on any GLP-1, want to start soon | Start an FDA-approved option | CagriSema isn’t available; waiting costs you months. |
| On Wegovy, it’s working and affordable | Stay the course; watch CagriSema | Don’t disrupt a plan that’s working for a drug you can’t get. |
| Plateaued on Wegovy 2.4 mg | Ask your clinician about Wegovy HD | It’s approved for exactly this — needing more reduction after 2.4 mg. |
| Hate needles | Ask about the Wegovy pill | It’s a once-daily oral semaglutide, now widely available. |
| Bad nausea on GLP-1s before | Don’t assume CagriSema will be gentler | Its side effects are also mostly stomach-related; ask a clinician first. |
| Tempted by a “CagriSema vial” online | Stop and verify with a clinician | The FDA says cagrilintide can’t be legally compounded. |
Should I wait for CagriSema, or start an FDA-approved option now?
Use this quick decision guide. It walks through the questions a clinician would ask, then points you to a clear next step.
- 1Are you currently on Wegovy (or another GLP-1)? If it’s working, covered, and tolerable → stay the course and watch the CagriSema decision.
- 2Is it covered or affordable? If cost is the problem → check your coverage and the cash-pay options below before changing anything.
- 3Have you plateaued at 2.4 mg? → ask your clinician about Wegovy HD.
- 4Are side effects limiting you? → talk to a clinician about dose, timing, and form — not a newer, unproven drug.
- 5Are injections a dealbreaker? → ask about the Wegovy pill.
- 6Do you need treatment in the next 30–90 days? → start an FDA-approved option now; CagriSema can be revisited later.
- 7Considering a “CagriSema” or cagrilintide product online? → don’t; it can’t be legally compounded.
Want this matched to your exact situation?
Get your personal wait-or-start answer in 60 seconds — no pressure, no purchase.
Start the quiz →How do side effects compare between CagriSema and Wegovy?
Both are dominated by gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — but the evidence base is different. Novo Nordisk reported that CagriSema’s most common side effects in REDEFINE 1 were gastrointestinal and mostly mild to moderate. Wegovy has a full FDA label with specific adult trial rates and warnings. More weight loss does not automatically mean easier to tolerate.
Caution: these numbers come from separate trials — REDEFINE 1 for CagriSema and the Wegovy injection’s adult trials for Wegovy — not a head-to-head. Read them as general patterns, not a precise nose-to-nose ranking.
| Side effect | CagriSema (REDEFINE 1) | Wegovy injection (adult trials) |
|---|---|---|
| Any GI side effect | 79.6% (vs 39.9% placebo) | 73% (vs 47% placebo) |
| Nausea | 55% (vs 12.6%) | 44% (vs 16%) |
| Vomiting | 26.1% (vs 4.1%) | 24% (vs 6%) |
| Constipation | 30.7% (vs 11.6%) | 24% (vs 11%) |
| Stopped treatment due to side effects | ~6% (vs 3.7%) | 6.8% (vs 3.2%) |
Sources: CagriSema figures from REDEFINE 1 (NEJM / Novo Nordisk). Wegovy figures from the Wegovy FDA prescribing information (adult weight-management trials).
CagriSema combines two medicines, and combinations tend to bring somewhat higher GI rates than semaglutide alone — but in REDEFINE 1, most events were mild to moderate and faded over time, and only about 6% stopped because of side effects. If tolerability is your biggest worry, the smartest move isn’t chasing the newest drug — it’s talking with a clinician about dose, timing, and which form fits you.
How much does CagriSema cost compared with Wegovy?
CagriSema has no U.S. price because it isn’t approved or launched — any number you see is a guess. Wegovy has real, current pricing across all three forms, and most people pay far less than list price. On cost certainty, Wegovy wins by default: you can know your price today.
Here’s what Wegovy actually costs right now. (Offers and dates change — re-verify on NovoCare and Wegovy.com before relying on them. The pen intro offer expires June 30, 2026.)
| Wegovy option | Current price |
|---|---|
| Wegovy pill (1.5 mg & 4 mg doses) | $149/month (4 mg offer through Aug 31, 2026, then $199) |
| Wegovy pen (0.25 & 0.5 mg, new patients) | $199/month for two fills through June 30, 2026 |
| Wegovy pen (0.25–2.4 mg, after intro) | $349/month |
| Wegovy HD (7.2 mg) | $399/month |
| With commercial insurance + savings card | As little as $0–$25/month (up to $100/month savings; government plans excluded) |
Source: NovoCare and Wegovy.com savings-offer terms. Wegovy’s list price is much higher — the offers above are the cheaper, official routes.
CagriSema price? Not announced. Not its insurance coverage, savings card, or telehealth availability either — none of that exists before approval and launch. Anyone quoting you a CagriSema price today is guessing.
A note on Medicare. Starting July 1, 2026, the Medicare GLP-1 Bridge is scheduled to give eligible Medicare Part D members a flat $50 copay per 30-day supply on certain weight-loss GLP-1s. CMS lists all Wegovy formulations (injection and tablets) as eligible, through December 31, 2027. The copay doesn’t count toward your deductible or out-of-pocket maximum, and the program runs outside the normal Part D benefit. Verify the current rules before counting on it. For more, see our GLP-1 insurance coverage guide.
If you’d rather know your price now than guess at CagriSema’s, check your Wegovy coverage with Ro’s free checker (sponsored affiliate link, opens in a new tab).
What if I’m already on Wegovy?
If Wegovy is working, covered, and tolerable, CagriSema is a “revisit later” item, not a reason to stop. If you’ve plateaued or it’s too expensive, the more useful conversation is about your current options — dose, Wegovy HD, the pill, or another approved medicine — not waiting on an unapproved drug.
Wegovy is working
Stay the course. Watch the CagriSema FDA decision, and reassess if and when it actually launches with real pricing.
Wegovy stopped working
Talk to your clinician about Wegovy HD, another approved GLP-1, or factors like protein, sleep, resistance training, and dose timing. A plateau usually has an available answer.
Wegovy is too expensive
Check your insurance, run Ro's free coverage checker, compare the manufacturer cash-pay offers above, and look at Sesame Care. See our cheapest FDA-approved GLP-1 without insurance guide.
Injections are the problem
Ask about the Wegovy pill — it's a once-daily oral semaglutide and now widely available. See our Wegovy pill cost guide.
CagriSema vs Wegovy vs Zepbound — where does each fit?
Wegovy is the established semaglutide, Wegovy HD is the higher-dose version, Zepbound is the approved tirzepatide competitor, and CagriSema is the investigational combo that isn’t out yet. This quick map exists so you don’t have to bounce back to search “but what about Zepbound?” after reading.
| Option | Status | Best-fit reader |
|---|---|---|
| Wegovy injection (2.4 mg) | FDA-approved | Wants the established weekly semaglutide shot |
| Wegovy pill | FDA-approved | Wants an oral, needle-free semaglutide |
| Wegovy HD (7.2 mg) | FDA-approved | Tolerated 2.4 mg, needs more weight reduction |
| Zepbound (tirzepatide) | FDA-approved | Wants strong head-to-head data — beat the standard Wegovy dose (20.2% vs 13.7%, SURMOUNT-5) and beat CagriSema (23.6% vs 20.2%, REDEFINE 4) |
| CagriSema | Investigational | Wants to monitor a future combo — not a choice today |
Still comparing approved GLP-1s?
Our free 60-second matching quiz points you to the option that fits your situation, insurance, and preferences.
Take the matching quiz →What most CagriSema vs Wegovy comparisons get wrong
Most comparisons treat CagriSema like something you can choose today, compare it only to the old Wegovy shot, and skip the legal risk around “CagriSema vials.” The honest comparison isn’t one trial percentage against another — it’s availability, FDA status, price certainty, tolerability, and the cost of waiting.
- 1
Calling CagriSema “available soon” without the gap.
FDA review, launch, insurance decisions, pharmacy stocking, and clinician adoption are separate steps that take time. “Late 2026” is an optimistic estimate, and timelines often slip.
- 2
Ignoring Wegovy HD and the Wegovy pill.
The Wegovy landscape in 2026 is not the Wegovy of 2024. Comparing CagriSema only to the old 2.4 mg shot is out of date. Wegovy HD (∼20.7%) and the Wegovy pill are both FDA-approved and available now.
- 3
Quoting only the best-case trial number.
We show both the “if taken as directed” and “counting everyone” figures, because everyday use lands closer to the lower one. A one-number headline makes a brand-new drug look more certain than it is.
- 4
Not warning about compounded cagrilintide.
The FDA says it can’t be legally compounded. A trustworthy page puts that front and center, not buried. Unapproved vials sold online carry real risks.
How we verified this comparison
We checked this page against primary and authoritative sources, and we’re clear about what we couldn’t verify because it doesn’t exist yet. That’s the difference between a reported page and a rewritten one.
| Item | What we found | Source |
|---|---|---|
| CagriSema FDA status | Application filed Dec 2025; not approved in U.S. or EU | Novo Nordisk |
| CagriSema ingredients | Cagrilintide 2.4 mg + semaglutide 2.4 mg | Novo Nordisk |
| REDEFINE 1 weight loss | 20.4% CagriSema vs 14.9% sema 2.4 mg (counting everyone); 22.7% vs 16.1% (if taken as directed) | NEJM / ADA |
| CagriSema side effects | Any GI 79.6%; nausea 55%; vomiting 26.1%; ~6% stopped | NEJM |
| REDEFINE 4 head-to-head | 20.2% CagriSema vs 23.6% Zepbound; failed non-inferiority | Novo Nordisk |
| Wegovy HD approval & data | Approved Mar 19, 2026; ~20.7% in STEP UP | FDA / Novo Nordisk |
| Wegovy pill | Approved Dec 22, 2025; 16.6% in OASIS 4; from $149/mo | Novo Nordisk |
| Wegovy side effects | Any GI 73%; nausea 44%; 6.8% stopped (adult trials) | Wegovy FDA label |
| SURMOUNT-5 (Zepbound vs Wegovy) | 20.2% vs 13.7% at 72 weeks | NEJM |
| Wegovy pricing | ~$149–$399/mo by form; $0–$25/mo with some insurance | NovoCare / Wegovy.com |
| Medicare GLP-1 Bridge | $50 copay, July 1, 2026–Dec 31, 2027; Wegovy eligible | CMS |
| Cagrilintide compounding | FDA: cannot be used in compounding under federal law | FDA |
What we could not verify (it doesn’t exist yet): CagriSema’s final FDA decision, brand/label details, U.S. price, insurance coverage, and telehealth availability. We’ll update this page when the FDA acts.
Frequently asked questions
Is CagriSema better than Wegovy?
In the REDEFINE 1 trial, CagriSema produced more average weight loss than the semaglutide 2.4 mg dose tested beside it — about 22.7% versus 16.1% if people stayed on treatment. But Wegovy is FDA-approved and available now, while CagriSema is still investigational, so Wegovy is the better real-world choice today.
Is CagriSema FDA approved?
No. Novo Nordisk filed its application in December 2025, and the FDA is reviewing it in 2026, with a decision widely expected late in the year. It is not approved in the U.S. or EU.
When will CagriSema be released?
If the FDA approves it, a launch could follow in late 2026 or early 2027. Drug timelines often shift, so treat earlier dates with caution.
Can you buy CagriSema online right now?
No. No legitimate U.S. pharmacy can sell FDA-approved CagriSema because it isn’t approved or available. Be especially cautious of “research,” “vial,” or “compounded CagriSema” offers.
Is compounded CagriSema legal?
No. CagriSema isn’t approved, and the FDA specifically states that cagrilintide cannot be used in compounding under federal law.
What is the main difference between CagriSema and Wegovy?
CagriSema combines semaglutide with cagrilintide, an amylin analogue that works on a second appetite pathway. Wegovy is semaglutide alone, now available as a weekly shot, a once-daily pill, and a higher-dose shot (Wegovy HD).
Should I wait for CagriSema?
Usually not, if you want treatment soon and can access an FDA-approved option now. Waiting makes more sense only if you’re stable, not in a hurry, and want to reassess after the FDA decides.
How much does Wegovy cost now?
Current self-pay offers range from about $149/month for certain Wegovy pill doses to $399/month for Wegovy HD, depending on dose, form, and offer dates. With commercial insurance and the savings card, eligible patients may pay as little as $0–$25/month.
Is Wegovy HD better than CagriSema?
There’s no direct head-to-head trial. Wegovy HD is FDA-approved and produced about 20.7% weight loss in STEP UP; CagriSema produced about 22.7% in the REDEFINE 1 “if taken as directed” analysis — but those are different trials, so neither can be called the winner over the other.
Does CagriSema come as a pill?
No. CagriSema’s application is for a once-weekly injection. Wegovy comes as both an injection and a once-daily pill.
What if I’m already on Wegovy and it’s working?
The practical move is usually to stay the course and watch the CagriSema FDA decision. Don’t stop a plan that’s working for a drug you can’t get yet.
Still not sure which GLP-1 program is right for you?
Take our free 60-second matching quiz. A few quick questions, a personalized action plan — no pressure, no purchase required.
Find My GLP-1 Path →Sources
- Novo Nordisk — REDEFINE 1 results and NEJM publication. GlobeNewswire
- New England Journal of Medicine — REDEFINE 1 (cagrilintide–semaglutide). NEJM
- Novo Nordisk — CagriSema FDA filing (Dec 18, 2025). PR Newswire
- Drugs.com — CagriSema FDA approval status. Drugs.com
- REDEFINE 4 head-to-head vs tirzepatide (primary endpoint not met). Drugs.com
- New England Journal of Medicine — STEP 1 (Wegovy 2.4 mg). NEJM
- FDA / Novo Nordisk — Wegovy HD approval & STEP UP (Mar 19, 2026). FDA.gov
- Novo Nordisk / PR Newswire — Wegovy pill FDA approval and OASIS 4. PR Newswire
- New England Journal of Medicine — SURMOUNT-5 (tirzepatide vs semaglutide). NEJM
- Wegovy FDA prescribing information (adverse reactions, discontinuation). FDA.gov
- NovoCare / Wegovy.com — savings offer & pricing. NovoCare
- CMS — Medicare GLP-1 Bridge (beneficiary information). CMS.gov
- FDA — Concerns with Unapproved GLP-1 Drugs (cagrilintide compounding). FDA.gov
- Ro — GLP-1 Insurance Coverage Checker. Ro.co